SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies, today ...

PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of ...

After seeing the successes of the likes of Pfizer (PFE) and Moderna (MRNA) in the news practically every day during this second year of the pandemic, the casual observer could be forgiven for assuming ...

It’s the time of year when we all get a little sentimental. We’re wrapping up work so we can shift to wrapping presents for under the tree. At Fierce Biotech, it’s no different. If you don’t know me, ...

Insider got exclusive data on the highest-paid CEOs in the pharma and biotech industries in 2021. The research firm MyLogIQ identified 15 CEOs that made at least $25 million last year. These leaders ...

For the last few years, Hong Kong has been the preferred financial hub for many Chinese health care companies to go public and raise money from global investors. “Biotechnology is today the ...

The FDA approval of Biogen's Alzheimer's disease drug Aduhelm was the biggest surprise. Several COVID-19 vaccine stocks skyrocketed well beyond expectations. Relatively few mergers and acquisitions ...

Initial public offerings by biotechnology companies are slowing after two record-setting years as the poor performance of some recent IPOs combined with economic and geopolitical uncertainties have ...

Despite the success of COVID vaccines and medicines, the biotech sector underperformed the broader market in 2021. The Medical-Biomedical and Genetics industry declined 21.6% in 2021 against the S&P ...

Biotech investor Brad Loncar shared with Insider his 10 predictions for 2022. He expected a rebound for biotech stocks after a down year in 2021. He also predicted hot research areas, which CEOs could ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...